[{"indications": "Indications\u00a0severe respiratory syncytial virus bronchiolitis in infants and children;\r\nin combination with peginterferon alfa or interferon alfa for chronic hepatitis C in patients without liver decompensation\r\n(see also section 5.3.3.2)", "name": "RIBAVIRIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.5 Respiratory syncytial virus", "RIBAVIRIN"], "cautions": "Cautions\u00a0Specific cautions for inhaled treatment\u00a0Maintain standard supportive respiratory and fluid management therapy; monitor electrolytes closely; monitor equipment for precipitation; pregnant\r\nwomen (and those planning pregnancy) should avoid exposure to aerosolSpecific cautions for oral treatment\u00a0Exclude pregnancy before treatment; effective contraception essential\r\nduring treatment and for 4 months after treatment in women and for\r\n7 months after treatment in men; routine\r\nmonthly pregnancy tests recommended; condoms must be\r\nused if partner of male patient is pregnant (ribavirin excreted in semen); cardiac disease (assessment including ECG recommended\r\nbefore and during treatment\u2014discontinue if deterioration); gout; determine full blood\r\ncount, platelets, electrolytes, serum creatinine, liver function tests\r\nand uric acid before starting treatment and then on weeks 2 and 4\r\nof treatment, then as indicated clinically\u2014adjust dose if adverse reactions or laboratory abnormalities develop\r\n(consult product literature); eye examination\r\nrecommended before treatment; eye examination also recommended\r\nduring treatment if pre-existing ophthalmological disorder or if decrease\r\nin vision reported\u2014discontinue treatment if ophthalmological disorder\r\ndeteriorates or if new ophthalmological disorder develops; test thyroid function before treatment and then every\r\n3 months in children; risk of growth retardation\r\nin children, the reversibility of which is uncertain\u2014if possible,\r\nconsider starting treatment after pubertal growth spurtInteractions: Appendix 1 (ribavirin)", "side-effects": "Side-effects\u00a0Specific side-effects for inhaled treatment\u00a0Worsening\r\nrespiration, bacterial pneumonia, and pneumothorax reported; rarely\r\nnon-specific anaemia and haemolysisSpecific side-effects for oral treatment\u00a0Haemolytic\r\nanaemia (anaemia may be improved by epoetin); also (in combination\r\nwith peginterferon alfa or interferon alfa) nausea,  vomiting, dyspepsia,\r\n abdominal pain, flatulence, constipation, diarrhoea, colitis, chest\r\npain, palpitation, tachycardia, peripheral oedema, changes in blood\r\npressure, syncope, flushing, cough, dyspnoea, headache, dizziness,\r\nasthenia, impaired concentration and memory, sleep disturbances, abnormal\r\ndreams, anxiety, depression, suicidal ideation (more frequent in children),\r\npsychoses, dysphagia, weight loss, dysphonia, paraesthesia, hypoaesthesia,\r\nataxia, hypertonia, influenza-like symptoms, thyroid disorders, hyperglycaemia,\r\nmenstrual disturbances, breast pain, prostatitis, sexual dysfunction,\r\nmicturition disorders, leucopenia, thrombocytopenia, lymphadenopathy,\r\ndehydration, hypocalcaemia, myalgia, arthralgia, hyperuricaemia, visual\r\ndisturbances, eye pain, dry eyes, hearing impairment, tinnitus, earache,\r\ndry mouth, taste disturbances, mouth ulcers, stomatitis, glossitis,\r\ntooth disorder, gingivitis, alopecia, pruritus, dry skin, rash (including\r\nvery rarely Stevens-Johnson syndrome and toxic epidermal necrolysis),\r\nincreased sweating, psoriasis, photosensitivity, and acne; less commonly pancreatitis, gastro-intestinal bleeding,\r\nand hypertriglyceridaemia; rarely peptic ulcer, arrhythmias,\r\ncardiomyopathy, myocardial infarction, pericarditis, stroke, interstitial\r\npneumonitis, pulmonary embolism, seizures, renal failure, vasculitis,\r\nrheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, optic\r\nneuropathy, and retinal haemorrhage; very rarely aplastic\r\nanaemia and peripheral ischaemia; in children also\r\ngrowth retardation (including decrease in height and weight), pallor,\r\ntachypnoea, hyperkinesia, virilism, and skin discoloration", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/127964.htm", "doses": ["See preparations below", "chronic hepatitis C (in combination with interferon alfa\r\nor peginterferon alfa), adult over\r\n18 years, body-weight under 75\u00a0kg, 400\u00a0mg in the morning and 600\u00a0mg\r\nin the evening; body-weight 75\u00a0kg and over, 600\u00a0mg twice daily"], "pregnancy": "Pregnancy\u00a0avoid; teratogenicity in animal studies;\r\nsee also Cautions above"}]